β-Glucuronidase-Cleavable Linkers: Precision Tools for ADC Payload Release
In the evolving landscape of antibody–drug conjugate (ADC) development, the design of cleavable linkers is a decisive factor in achieving both therapeutic efficacy and selectivity.
Among the various enzymatically cleavable linker strategies, β-glucuronidase-cleavable linkers have established themselves as a robust and well-characterized option.
Why β-Glucuronidase-Cleavable Linkers?
These linkers remain stable in systemic circulation yet are selectively cleaved by β-glucuronidase—an enzyme commonly overexpressed in:
The necrotic cores of tumors
The broader tumor microenvironment in several solid malignancies
This ensures tumor-targeted payload release, while minimizing off-target toxicity and systemic side effects.

Structural Design and Variations
A typical β-glucuronidase-cleavable linker features a glucuronic acid unit conjugated at the anomeric position to a self-immolative spacer.
The aminobenzyl alcohol motif is the classical choice for this role
Several derivatives have since been developed to fine-tune performance, including:
Differently substituted aminobenzyl alcohols
Extended benzyl alcohol variants
Heteroaryl-linked spacers
These structural modifications allow chemists to optimize:
Payload release kinetics
Aqueous solubility
Overall linker stability
Opportunities for ADC Development
This structural diversity provides researchers with the flexibility to tailor β-glucuronidase-cleavable linkers to specific therapeutic goals, while retaining the robust enzymatic trigger that ensures reliable release.
For ADC developers, the approach offers a balance of stability and tumor selectivity—key factors for advancing payload delivery strategies.
SigutLabs Expertise
At SigutLabs, we specialize in the custom synthesis of ADC linkers, including β-glucuronide linkers designed to meet the unique requirements of your ADC program.
Whether your goal is to maximize stability, modulate release kinetics, or explore new spacer architectures, our team is ready to support your innovation.
Contact us to discuss how we can help advance your next ADC project.
OUR CASE STUDY
Scale-up to accelerate drug discovery
Our experience helped overcome development hurdles for potential cancer & mental health drugs.
Read moreEmpowering neuro research with pro-N6pA
Sigut Labs scaled up pro-N6pA production, simplifying AMPylation research & boosting accessibility.
Read moreADC development leaps with new linkers
Novel linker design expedited ADC advancement, leading to promising lead compounds faster.
Read moreLincomycin derivative scale-up
Over 30 g of the desired product with exceptional purity was obtained through our optimized procedure.
Read morePurifying 350 kg of vitamin K2 oil
Our innovative scale-up technology helped to reduce the client’s purification process from days to hours.
Read more
Custom synthesis
Providing for a custom synthesis of previously reported molecules using described synthetic procedures.

Contract research
Developing novel synthetic routes to provide undescribed compounds in organic, bioorganic, and medicinal chemistry.

Scale-Up
Helping you go from lab scales to an industrial scale by applying our cutting-edge instrumentation.

Our Experts


Partners & distributors











